Ernexa Therapeutics Inc. Proceeds from Divestiture of Businesses
Ernexa Therapeutics Inc. (ERNA) reported Proceeds from Divestiture of Businesses of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2023-03-20
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for the quarter ending 2022-12-31 was $0.00.
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for the quarter ending 2022-09-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for the quarter ending 2022-06-30 was $0.00.
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for fiscal 2021 was $119.00K.
- Ernexa Therapeutics Inc. proceeds from divestiture of businesses for fiscal 2020 was $0.00.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 3 month as first filed | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 6 month as first filed | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 9 month as first filed | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-03-20 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $0.00 derived: sum of 4 quarters · filed 2023-03-20 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-07-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $0.00 derived: sum of 4 quarters · filed 2023-03-20 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $119.00K 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $119.00K 10-Q · filed 2022-11-14 | $118.59K 10-Q · filed 2021-11-12 | $119.00K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $119.00K 10-Q · filed 2022-08-11 | $118.59K 10-Q · filed 2021-08-13 | $119.00K derived: sum of 3 quarters · filed 2022-08-11 | $119.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $119.00K 10-Q · filed 2022-07-01 | $118.59K 10-Q · filed 2021-05-17 | $119.00K derived: sum of 2 quarters · filed 2022-07-01 | $119.00K derived: sum of 3 quarters · filed 2022-07-01 | $119.00K derived: sum of 4 quarters · filed 2022-07-01 | ||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $0.00 derived: sum of 2 quarters · filed 2022-07-01 | $0.00 derived: sum of 3 quarters · filed 2022-07-01 | $0.00 10-K/A · filed 2022-07-01 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | |||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |